<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750645</url>
  </required_header>
  <id_info>
    <org_study_id>COLS-201207</org_study_id>
    <nct_id>NCT01750645</nct_id>
  </id_info>
  <brief_title>Management of the Idiopathic Overactive Bladder With Botulinum Toxin: Systematic Review</brief_title>
  <official_title>Management of the Idiopathic Overactive Bladder With Intradetrusor Injection of Type-A Botulinum Toxin: Systematic Review of the Literature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clínica Infantil Colsubsidio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clínica Infantil Colsubsidio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overactive bladder is defined as a syndrome composed of urgency, increased urinary frequency,&#xD;
      and sometimes urinary incontinence; its etiology may be characterized as neurogenic or&#xD;
      non-neurogenic (i.e., idiopathic). This illness has a great impact in quality of life and one&#xD;
      of the available treatments is the injection of Botulinum Toxin. This study aims to review&#xD;
      the efficacy and safety of type-A Botulinum Toxin in the management of Idiopathic Overactive&#xD;
      Bladder. A systematic search was performed in MEDLINE, EMBASE, CENTRAL and LILACS, and the&#xD;
      controlled randomized clinical trials were chosen to review with the CONSORT criteria by&#xD;
      independent reviewers. Outcomes analyzed were the efficacy of the intervention for relieving&#xD;
      the symptoms (urgency, frequency and urgency incontinence), adverse events to treatment,&#xD;
      change in quality of life and urodynamic measures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence)</measure>
    <time_frame>Minimun follow-up period of 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events to treatment (urinary retention and urinary tract infections)</measure>
    <time_frame>Minimun follow-up period of 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Minimun follow-up period of 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urodynamic measures</measure>
    <time_frame>Minimun follow-up period of 12 weeks</time_frame>
    <description>Increase in maximum cystometric capacity, first desire to void, normal desire to void, postvoid residual volume, and the presence/abscence of detrusor overactivity.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <condition>Urinary Bladder, Overactive</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intradetrusor Injection of Type-A Botulinum Toxin</intervention_name>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Other interventions analyzed according to protocol</intervention_name>
    <description>Placebo&#xD;
Different dosage of Type-A Botulinum Toxin injected&#xD;
Anticholinergic drugs</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with idiopathic overactive bladder&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Controlled randomized clinical trials&#xD;
&#xD;
          -  Adult patients diagnosed with idiopathic overactive bladder&#xD;
&#xD;
          -  Language of the study: english&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of neurogenic overactive bladder&#xD;
&#xD;
          -  Patients under 18 years old&#xD;
&#xD;
          -  Use of Type-B Botulinum Toxin as the intervention&#xD;
&#xD;
          -  Other types of studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo E López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Infantil Colsubsidio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica Infantil Colsubsidio</name>
      <address>
        <city>Bogotá DC</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clínica Infantil Colsubsidio</investigator_affiliation>
    <investigator_full_name>Hugo Enrique López, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

